Rocket Lab's Neutron Setback Tests Investor Nerves as Analysts Split on the Damage

Rocket Lab's stock has come under heavy fire, and the trigger is not a mystery. The company pushed the maiden flight of its Neutron rocket from the originally targeted fourth quarter of 2026 into 2027, a schedule change that has rippled through both the share price and the analyst community.

The selling has been brutal. On Thursday the stock shed 11% to trade at EUR 47.15, well below its 50-day moving average of EUR 60.59. The prior session had already brought a 7.2% decline to EUR 49.30. Against the 52-week high of EUR 133.80, the retreat is stark.

What Went Wrong With Neutron

At the heart of the delay were manufacturing and process issues involving a fuel dome on the first stage. Rocket Lab confirmed in a mandatory disclosure that development work and process improvements are ongoing. The upshot: the company's entry into the lucrative medium-payload segment slides further into the future.

Technical hurdles of this kind are hardly exotic in aerospace. Building rockets means operating at the outer edges of what is physically achievable, and a postponement aimed at fixing defects before a first test flight is, from an engineering standpoint, the sensible call. A failure on the launch pad during a debut attempt would inflict far greater damage on both confidence and the balance sheet than a calendar slip ever could.

The Analyst Divide

Institutional observers have responded with notably more composure than the tape would suggest. KeyBanc's Michael Leshock trimmed his price target to USD 100 from USD 135, citing the revised Neutron timeline and the broader valuation pressure weighing on high-growth space names. Crucially, he kept his Buy rating and Overweight stance intact.

Stifel went further in its conviction, reaffirming its Buy rating on Thursday and holding firm on a USD 132 target. Other market watchers shaved their own objectives modestly but stayed anchored in an optimistic overall tone. The gap between the sharp selloff and these steady assessments tells its own story: on Wall Street, few question Rocket Lab's long-term relevance — what is in doubt is the short-term risk appetite of retail investors.

Insider Activity Draws Scrutiny

Alongside the project revisions, management transactions have attracted attention. On October 1, Rocket Lab's chief financial officer disposed of 140,157 company shares. The sales were executed under a pre-arranged trading plan in accordance with Rule 10b5-1, which automates transactions by senior staff.

What Matters From Here

The road ahead hinges on how quickly the announced process optimizations take hold. Space is a capital-hungry industry, and every extra month without Neutron launches represents lost ground in the race for future payload contracts. Even so, the case for the business model retains its pull: Rocket Lab possesses genuine technological depth and has demonstrated operational discipline in the past.

For those who had bet on a swift rally, the recent slide has been painful. Yet anyone who priced in the inherent risk of an aerospace venture is likely to read this episode as a clearing out of overstretched near-term expectations rather than a fundamental rupture. The market punishes delays severely — but the underlying opportunity to become a fixture in the launch vehicle market remains untouched.